Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
 & Lead Plaintiff Deadline - March 27, 2017 - EconoTimes)
NEW YORK, March 24, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against PixarBio Corporation (“PixarBio” or the “Company”) (OTCMKT:PXRB) and certain of its officers, on behalf of a class who purchased PixarBio securities: (1) pursuant and/or traceable to PixarBio’s private placement that closed on October 30, 2016; and/or (2) publicly traded on the open market from October 31, 2016 through January 20, 2017, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/pxrb.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) the market for PixarBio’s securities exhibited manipulative or deceptive activities; (2) PixarBio’s statements in press releases, third-party promotional materials, and its Form S-1 regarding, among other things, PixarBio’s business combinations and current shareholders; the identity and qualifications of key shareholders and employees and its current and prospective development efforts lacked accuracy; and (3) consequently, Defendants’ public statements were materially false and misleading at all relevant times.
On January 23, 2017, the SEC disclosed the temporary suspension of PixarBio trading “because the market for the security appears to reflect manipulative or deceptive activities and because of questions regarding the accuracy of assertions by PixarBio in press releases and its Form S-1 concerning, among other things: (1) the company’s business combinations and current shareholders; (2) the identity and qualifications of key shareholders and employees; and (3) the company’s current and prospective development efforts.”
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/pxrb or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in PixarBio you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
